Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study

A month after securing approval for cluster headaches, Lilly’s $LLY migraine drug Emgality has scored in a late-stage trial as a preventive treatment for chronic and episodic migraines in patients who have failed more than two standard-of-care prophylactic treatments.